News

GRP named a top economic development organization in the U.S.

RICHMOND, VA – The Greater Richmond Partnership (GRP) was named among the top 20 economic development organizations in the nation according to Site Selection magazine, a national publication targeting site location professionals and corporate executives making relocation decisions.

The 2022 Mac Conway Awards for Excellence in Economic Development, named in honor of Site Selection founding publisher H. McKinley ‘Mac’ Conway, are awarded annually to the top economic development organizations in the country determined by an index of corporate job creation and facility-related capital investment data calculated both cumulatively and per capita. This marks the first time since 2015 the publication has recognized GRP for outstanding work in its field. It was named a top organization four previous years plus two honorable mentions since its inception in 1994.

“In the last two years, we’ve done a lot of work to come out of the pandemic as a stronger and more focused region and organization. This includes benchmarking best of class regions and regional groups,” said Jennifer Wakefield, President and CEO of GRP. “We are thrilled to be recognized among the best economic development organizations in the country yet again. It’s a testament to our strong public-private partnership and the collaboration found throughout the region to bring jobs and investment to Greater Richmond.”

Earlier this year, Site Selection ranked Greater Richmond as the 3rd top metro for economic development projects per capita for 2021.

Read more here.

Recent News

09/21/2022

HemoShear Therapeutics Advancing Novel Modulators Against Second Target for Horizon Therapeutics’ Gout Discovery Pipeline

HemoShear Therapeutics, Inc., a privately held clinical stage biotechnology company, has earned a milestone payment for the advancement of potential lead product candidates against a second target for the treatment of gout under its collaboration with Horizon Therapeutics plc (Nasdaq: HZNP). This milestone marks the fifth payment that HemoShear has earned in accordance with the

09/21/2022

Kaléo Announces First U.S. Department of Defense Supply Contract for the Rapid Opioid Countermeasure System (ROCS) Antidote for Ultra-Potent Weaponized Opioids

Kaléo, a privately held commercial-stage U.S. pharmaceutical company, announced the execution of the first contract with the U.S. Department of Defense (DoD) for the procurement of the Rapid Opioid Countermeasure System (ROCS), a 10 mg Naloxone Auto-injector (naloxone hydrochloride injection) antidote for ultra-potent weaponized opioids. The contract includes an award for the manufacture and delivery

09/20/2022

Embody, Inc. Announces $10.4 Million Series C Funding Round

Embody, Inc., a privately-held medical device company focused on soft tissue healing, announced that it closed a $10.4 million Series C funding round led by Genesis Innovation Group’s cultivate(MD) Capital Funds LP. The financing will enable Embody to expand its world-class operations, post-market clinical studies of the recently launched Tapestry RC System for rotator cuff